Louie Fidaxomicin

Fidaxomicin versus Vancomycin for Clostridium difficile Infection

Paziente / Popolazione Intervento / Esposizione Confronto Esito

In 629 patients with Clostridium difficile infection, fidaxomicin reduced recurrence at 4 weeks compared with oral vancomycin with similar clinical cure.

629

Disegno

Double-blind RCT

Esito

Clinical cure and recurrence

Rilevanza

RisultatoCure similar (~88 %); recurrence 15.4 % vs 25.3 % — fewer with fidaxomicin in non-NAP1 strains.

Louie TJ, et al. N Engl J Med. 2011;364(5):422-431. 10.1056/NEJMoa0910812

Discussione e critica

Established fidaxomicin as the preferred agent for initial and first-recurrence CDI — now reflected in IDSA/SHEA 2021 guidance.